Abstract
Sensitivity to the tumoricidal effect of ZIKV on high-risk neuroblastoma tumors is dependent on CD24 expression, offering a prognostic marker for this oncolytic therapy in an extensive array of CD24-expressing cancers.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have